American Society of Hirudotherapy

Linear Peptides Containing d-Leucine with Neuroprotective Activities from the Leech Whitmania pigra Whitman

Research article published in Journal of natural products (2019)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Drug DevelopmentZhang ZY et al. · Journal of natural products, 2019

Abstract

Three new linear peptides containing d-leucine, named whitmantides A-C (1-3), were isolated from the dried whole bodies of Whitmania pigra Whitman. Their structures with absolute configurations were elucidated by Edman degradation, mass spectrometry, Marfey's analysis, and solid-phase synthesis. It is the first time that peptides containing d-amino acid in leeches were discovered. Compounds 1-3 displayed neuroprotective activities against oxygen-glucose deprivation/reperfusion injury on Neuro-2a cells. In addition, ex vivo serum stability tests showed that 1-3 were resistant to protease degradation.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAnimalsLeechesLeucineNeuroprotective AgentsPeptides

Summary

Whitmantides A-C, three new d-leucine-containing linear peptides from dried Whitmania pigra whole bodies, are the first d-amino-acid peptides discovered in leeches; all three protected Neuro-2a cells from oxygen-glucose deprivation/reperfusion injury and resisted serum protease degradation.

Why This Matters for Hirudotherapy

This study isolated three new linear peptides containing d-leucine, named whitmantides A–C, from dried whole bodies of the leech Whitmania pigra, marking the first reported discovery of d-amino-acid-containing peptides in leeches. Structures were determined by Edman degradation, mass spectrometry, Marfey's analysis, and solid-phase synthesis. The compounds showed neuroprotective activity against oxygen-glucose deprivation/reperfusion injury in Neuro-2a cells and resisted protease degradation in ex vivo serum stability tests. Findings are preclinical and limited to cell-based and serum-stability assays, with no in-vivo or clinical evidence.

Citation

Reference (Vancouver style)

Zhang ZY, Ma N, Tao LJ, Gong XY, Ye WC, Wang L. Linear Peptides Containing d-Leucine with Neuroprotective Activities from the Leech Whitmania pigra Whitman. J Nat Prod. 2019;82(8):2349-2353. doi:10.1021/acs.jnatprod.9b00322. PMID: 31361480

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.